Halozyme Therapeutics (HALO) EBITDA Margin Growth (1y) (2011 - 2026)
Halozyme Therapeutics (HALO) EBITDA Margin Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1,552.00 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1,536.00 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -170.00 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1,049.00 |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Halozyme Therapeutics | 9.55 Bn | 9.23 Bn | 297.47 Mn | -446.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -446.00 |
| Dec 31, 2025 | -7,945.00 |
| Sep 30, 2025 | 526.00 |
| Jun 30, 2025 | 1,148.00 |
| Mar 31, 2025 | 466.00 |
| Dec 31, 2024 | 1,497.00 |
| Sep 30, 2024 | 1,539.00 |
| Jun 30, 2024 | 794.00 |
| Mar 31, 2024 | 1,559.00 |
| Dec 31, 2023 | 287.00 |
| Sep 30, 2023 | 101.00 |
| Jun 30, 2023 | 2,038.00 |
| Mar 31, 2023 | -3,134.00 |
| Dec 31, 2022 | -1,437.00 |
| Sep 30, 2022 | -2,540.00 |
| Jun 30, 2022 | -4,583.00 |
| Mar 31, 2022 | 753.00 |
| Dec 31, 2021 | -836.00 |
| Sep 30, 2021 | 356.00 |
| Jun 30, 2021 | 1,467.00 |